[go: up one dir, main page]

BR9910589A - Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula - Google Patents

Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula

Info

Publication number
BR9910589A
BR9910589A BR9910589-6A BR9910589A BR9910589A BR 9910589 A BR9910589 A BR 9910589A BR 9910589 A BR9910589 A BR 9910589A BR 9910589 A BR9910589 A BR 9910589A
Authority
BR
Brazil
Prior art keywords
humanized antibody
verotoxin
risk
vtm1
treat
Prior art date
Application number
BR9910589-6A
Other languages
English (en)
Inventor
Yoh-Ichi
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Publication of BR9910589A publication Critical patent/BR9910589A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ANTICORPO HUMANIZADO, PROCESSO PARA PRODUZIR ANTICORPO HUMANIZADO VTM1-1, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA TRATAR UM PACIENTE SOFRENDO OU EM RISCO DOS EFEITOS TóXICOS DE UMA VEROTOXINA, E, LINHAGEM DE CéLULA" A invenção provê anticorpos humanizados que especificamente se ligam a e preferivelmente neutralizam verotoxina II (VT2). Os anticorpos são utilizáveis para o tratamento de pacientes sofrendo de ou em risco de sofrer efeitos tóxicos de verotoxina.
BR9910589-6A 1998-05-20 1999-05-19 Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula BR9910589A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (1)

Publication Number Publication Date
BR9910589A true BR9910589A (pt) 2001-01-16

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910589-6A BR9910589A (pt) 1998-05-20 1999-05-19 Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula

Country Status (19)

Country Link
US (1) US7846435B1 (pt)
EP (1) EP1079856B1 (pt)
JP (1) JP4044733B2 (pt)
KR (1) KR100548167B1 (pt)
CN (1) CN1330375C (pt)
AT (1) ATE335504T1 (pt)
AU (1) AU748852B2 (pt)
BR (1) BR9910589A (pt)
CA (1) CA2328485C (pt)
DE (1) DE69932719T2 (pt)
DK (1) DK1079856T3 (pt)
ES (1) ES2270598T3 (pt)
IL (2) IL139571A0 (pt)
NO (1) NO326197B1 (pt)
NZ (1) NZ508119A (pt)
PT (1) PT1079856E (pt)
RU (1) RU2217166C2 (pt)
WO (1) WO1999059629A1 (pt)
ZA (1) ZA200006370B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
AU2010206800B2 (en) 2009-01-23 2016-06-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 2 protein
CA2913702C (en) * 2013-05-27 2023-08-01 Inmunova S.A. Chimeras of brucella lumazine synthase and beta subunit of ab5 toxins
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) * 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
JPH11506424A (ja) 1995-03-24 1999-06-08 オフィディアン ファーマシューティカルズ インコーポレーテッド ベロ毒素産生大腸菌に対する治療
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
EP1079856A4 (en) 2002-03-13
AU748852B2 (en) 2002-06-13
AU4090499A (en) 1999-12-06
JP2002515230A (ja) 2002-05-28
KR100548167B1 (ko) 2006-01-31
HK1036215A1 (en) 2001-12-28
NO20005833D0 (no) 2000-11-17
DE69932719D1 (de) 2006-09-21
KR20010052367A (ko) 2001-06-25
RU2217166C2 (ru) 2003-11-27
ZA200006370B (en) 2001-08-22
ATE335504T1 (de) 2006-09-15
DE69932719T2 (de) 2007-09-13
DK1079856T3 (da) 2006-12-04
CN1301175A (zh) 2001-06-27
WO1999059629A1 (en) 1999-11-25
IL139571A0 (en) 2002-02-10
EP1079856B1 (en) 2006-08-09
NZ508119A (en) 2003-06-30
JP4044733B2 (ja) 2008-02-06
PT1079856E (pt) 2006-12-29
US7846435B1 (en) 2010-12-07
CN1330375C (zh) 2007-08-08
IL139571A (en) 2009-09-22
ES2270598T3 (es) 2007-04-01
CA2328485A1 (en) 1999-11-25
CA2328485C (en) 2011-05-03
NO326197B1 (no) 2008-10-13
NO20005833L (no) 2001-01-15
EP1079856A1 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
RU2421464C2 (ru) Человеческие антитела к il-13 и их терапевтическое применение
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
IL178121A (en) Anti-cs-1 antibodies for the treatment of multiple myeloma
BRPI0407058A (pt) Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
ATE361100T1 (de) Methode zur krebs-behandlung mit anti- neurotrophin mittel
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
KR101155294B1 (ko) 면역특이적으로 ＢＬｙＳ에 결합하는 항체
BR0011000A (pt) Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
BR0315042A (pt) Terapia para o tratamento de aterosclerose baseada em imunização passiva por peptìdeo
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
BR9910589A (pt) Anticorpo humanizado, processo para produzir anticorpo humanizado vtm1-1, composição farmacêutica, e, processo para tratar um paciente sofrendo ou em risco dos efeitos tóxicos de uma verotoxina, e, linhagem de célula
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19
DE60020353D1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
BR112021024401A2 (pt) Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
EP1370697A4 (en) PEROXYREDOXIN-BASED MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV-1 INFECTIONS AND METHODS OF USE

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TEIJIN LIMITED (JP) , PDL BIOPHARMA, INC. (US)

Free format text: NOME ALTERADO DE: PROTEIN DESIGN LABS, INC.

B25G Requested change of headquarter approved

Owner name: TEIJIN LIMITED (JP) , PDL BIOPHARMA, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020100102715/RJ DE 03/11/2010.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 17A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/12 (2006.01), A61K 38/00 (2006.0